Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Ascletis Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)
2021-05-05 08:30
Clarity receives US FDA clearance of IND Application for its next-generation PSMA theranostic products
2021-05-04 21:08
IVM-MS2, 'The Most Compact All-in-One IntraVital Two-Photon Microscopy System in the World'
2021-05-03 23:47
Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study
2021-05-03 20:30
BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction
2021-05-03 20:00
Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study
2021-04-30 18:00
Revotek Deploys Its Bioink Technology to Research Institutes
2021-04-29 21:30
BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH(R) Diagnostic
2021-04-29 20:56
Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report
2021-04-29 20:30
Artificial Intelligence helps IVF patients avoid invasive embryo genetic testing
2021-04-29 19:47
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
2021-04-29 08:34
Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration
2021-04-29 08:00
Novaliq Announces More than 50% Patients Enrolled in CyclASol® Phase 3 Dry Eye Disease Trial ESSENCE-2
2021-04-28 20:00
CROs dMed and Clinipace Merge to Accelerate Customer Success
2021-04-28 20:00
Turn Biotechnologies completes latest round of funding
2021-04-28 19:50
GenScript Launches Research-Grade Lentiviral Vector Packaging Service
2021-04-28 19:30
Samsung Biologics Reports First Quarter 2021 Financial Results
2021-04-28 16:37
TCI Co., Ltd. becomes Asia's first biotechnology company whose climate ambitions are validated by SBTi
2021-04-27 15:53
DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone
2021-04-27 09:23
EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology
2021-04-27 09:00
1
321
322
323
324
325
526